Retrophin Receives a Buy from JMP Securities

By Carrie Williams

JMP Securities analyst Liisa Bayko reiterated a Buy rating on Retrophin (NASDAQ: RTRX) today. The company’s shares opened today at $21.17.

According to, Bayko is a 4-star analyst with an average return of 4.3% and a 53.0% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Anthera Pharmaceuticals, and Conatus Pharmaceuticals.

Currently, the analyst consensus on Retrophin is Strong Buy and the average price target is $35, representing a 65.3% upside.

In a report issued on November 3, BMO Capital also reiterated a Buy rating on the stock with a $40 price target.

The company has a one year high of $24.57 and a one year low of $11.60. Currently, Retrophin has an average volume of 720.3K.

Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RTRX in relation to earlier this year. Most recently, in March 2016, Jeffrey Meckler, a Director at RTRX bought 5,000 shares for a total of $76,550.

Retrophin, Inc. is a fully integrated biopharmaceutical company, which develops pharmaceutical products for the treatment of rare diseases. It is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.